Bloomberg News

Medigus Surges After It Says FDA Decision Expected Soon

May 02, 2012

Medigus Ltd. (MDGS) rose the most in two days after saying it expects a decision in the “near future” by the U.S. Food and Drug Administration on an application to market its SRS device to treat gastroesophageal-reflux disease.

The shares of the developer of endoscopic procedures and devices rose 11 percent, the most since April 30, to 1.14 shekels at 11:06 a.m. in Tel Aviv, giving the company a market value of 95 million shekels ($25 million).

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Hollywood Goes YouTube
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus